AD treatment significantly reduced the phosphorylation of p38 mitogen-activated protein kinase (MAPK) and ERK1/2 [20], which is required for the activation of reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and ROS production [61], thus reducing the NET formation in a ROS-dependent manner. This evidence concerns the gene MAPK14 and Alzheimer disease.